DDPDGENES

Identification of genes important for human midbrain dopamine neuron development and Parkinson’s disease

 Coordinatore KAROLINSKA INSTITUTET 

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Dr.
Nome: Blomstrand
Cognome: Jill
Email: send email
Telefono: 46852487687

 Nazionalità Coordinatore Sweden [SE]
 Sito del progetto http://www.ddpdgenes.eu
 Totale costo 3˙700˙382 €
 EC contributo 2˙817˙939 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2011-two-stage
 Funding Scheme CP-FP
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-01-01   -   2015-12-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Dr.
Nome: Blomstrand
Cognome: Jill
Email: send email
Telefono: 46852487687

SE (STOCKHOLM) coordinator 1˙036˙045.00
2    ORYZON GENOMICS SA

 Organization address address: CL BALDIRI REIXAC 10 12
city: BARCELONA
postcode: 8028

contact info
Titolo: Dr.
Nome: Carlos
Cognome: Buesa Arjol
Email: send email
Telefono: +34 93 5151313
Fax: +34 93 3774028

ES (BARCELONA) participant 450˙349.00
3    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

 Organization address address: BATIMENT CE 3316 STATION 1
city: LAUSANNE
postcode: 1015

contact info
Titolo: Dr.
Nome: Henry
Cognome: Markram
Email: send email
Telefono: 41216939537

CH (LAUSANNE) participant 448˙460.00
4    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

 Organization address address: The Old Schools, Trinity Lane
city: CAMBRIDGE
postcode: CB2 1TN

contact info
Titolo: Dr.
Nome: Roger
Cognome: Barker
Email: send email
Telefono: +44 1223 331160
Fax: +44 1223 331174

UK (CAMBRIDGE) participant 448˙458.80
5    FUNDACION INSTITUTO DE INVESTIGACION BIOMEDICA Y DESARROLLO TECNOLOGICO INBIOMED

 Organization address address: PASEO MIKELETEGI BAJO PARQUE TECNOLOGICO DE SAN SEBASTIAN 61
city: SAN SEBASTIAN
postcode: 20009

contact info
Titolo: Ms.
Nome: Maider
Cognome: Goyena Ibargoitia
Email: send email
Telefono: +34 943309064
Fax: +34 943308222

ES (SAN SEBASTIAN) participant 434˙627.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

unrecognized    midbrain    human    genes    subtypes    cell    loss    neurons    expression    stem    pd    developmental    pathogenesis    da   

 Obiettivo del progetto (Objective)

'The goal of this project is to determine whether the expression of developmental genes in defined subpopulations of DA neurons contributes to the specification of currently unrecognized midbrain DA neuron subtypes and whether their missexpression may contribute to the loss of DA neurons in the adulthood and to the pathogenesis of PD.

Many developmental genes have been found to be implicated in the maintenance of midbrain DA neurons at postnatal and adult stages, as assessed by the loss of DA neurons in transgenic mice heterozygous for: Nurr1, Pitx3, FoxA2, en1. On the other hand, genes involved in the pathogenesis of genetic forms of PD, such as Lrkk2 and PINK1, do not cause cell death. In this project we hypothesize that a disregulation of the expression of developmental genes may play a previously unrecognized role in PD.

We propose to identify subtypes of midbrain DA neurons at a molecular and functional level in: (i) the developing rodent and human ventral midbrain (VM), (ii) human neural and embryonic stem cell preparations differentiated into midbrain DA neurons, and (iii) DA neurons derived from induced pluripotent stem (iPS) cells generated from control and PD patients.'

Altri progetti dello stesso programma (FP7-HEALTH)

OPTATIO (2012)

OPtimizing TArgets and Therapeutics In high risk and refractOry Multiple Myeloma

Read More  

EIS (2009)

Development of a European Implementation Score for measuring implementation of research into healthcare practice using vascular disease as an example

Read More  

SICA-HF (2009)

Studies Investigating Co-morbidities Aggravating Heart Failure

Read More